Literature DB >> 4734404

Formation and function of a complex of the C3 proactivator with a protein from cobra venom.

N R Cooper.   

Abstract

The role of C3 proactivator (C3PA) and a factor isolated from cobra venom (CoF) in the formation of a principle able to cleave C3 was investigated. The results clearly demonstrate two modes of interaction of C3PA with CoF. In isolated form, C3PA and CoF were found to form a reversible protein-protein complex in free solution. This complex had some C3 cleaving activity. In the presence of minute amounts of a partially purified normal serum substance, factor D, the C3PA-CoF complex was stabilized and its efficiency in cleaving C3 was greatly increased. Factor D is thus an activator of C3PA. A firm complex composed of C3PA and CoF, and possessing C3 cleaving activity, was also formed by addition of CoF to serum.

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4734404      PMCID： PMC2139485          DOI： 10.1084/jem.137.2.451

Source DB:  PubMed          Journal:  J Exp Med        ISSN： 0022-1007            Impact factor:   14.307


  21 in total

1.  A method of trace iodination of proteins for immunologic studies.

Authors:  P J McConahey; F J Dixon
Journal:  Int Arch Allergy Appl Immunol       Date:  1966

2.  Studies on the mode of action of the fifth, sixth and seventh component of human complement in immune haemolysis.

Authors:  U R Nilsson; H J Müller-Eberhard
Journal:  Immunology       Date:  1967-07       Impact factor: 7.397

3.  The biologic activities of guinea pig antibodies. II. Modes of complement interaction with gamma 1 and gamma 2-immunoglobulins.

Authors:  A L Sandberg; A G Osler; H S Shin; B Oliveira
Journal:  J Immunol       Date:  1970-02       Impact factor: 5.422

4.  Passive hemolysis by serum and cobra venom factor: a new mechanism inducing membrane damage by complement.

Authors:  R J Pickering; M R Wolfson; R A Good; H Gewurz
Journal:  Proc Natl Acad Sci U S A       Date:  1969-02       Impact factor: 11.205

Review 5.  A molecular concept of immune cytolysis.

Authors:  H J Muller-Eberhard; U R Nilsson; A P Dalmasso; M J Polley; M A Calcott
Journal:  Arch Pathol       Date:  1966-09

6.  [Isolation and properties of a beta-glycoprotein from human serum].

Authors:  H Haupt; K Heide
Journal:  Clin Chim Acta       Date:  1965-10       Impact factor: 3.786

7.  Two anticomplementary factors in cobra venom: hemolysis of guinea pig erythrocytes by one of them.

Authors:  M Ballow; C G Cochrane
Journal:  J Immunol       Date:  1969-11       Impact factor: 5.422

8.  A new concept of immunosuppression in hypersensitivity reactions and in transplantation immunity.

Authors:  R A Nelson
Journal:  Surv Ophthalmol       Date:  1966-08       Impact factor: 6.048

9.  Formation and functional significance of a molecular complex derived from the second and the fourth component of human complement.

Authors:  H J Müller-Eberhard; M J Polley; M A Calcott
Journal:  J Exp Med       Date:  1967-02-01       Impact factor: 14.307

10.  The derivation of two distinct anaphylatoxin activities from the third and fifth components of human complement.

Authors:  C G Cochrane; H J Müller-Eberhard
Journal:  J Exp Med       Date:  1968-02-01       Impact factor: 14.307
View more
  20 in total

1.  Purification of cobra venom factor from phospholipase A contaminant.

Authors:  P J Lachmann; L Halbwachs; A Gewurz; H Gewurz
Journal:  Immunology       Date:  1976-12       Impact factor: 7.397

2.  Effects of two types of cobra venom factor on porcine complement activation and pulmonary artery pressure.

Authors:  A K Cheung; C J Parker; L Wilcox
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

Review 3.  The effects of bacterial endotoxins on host mediation systems. A review.

Authors:  D C Morrison; R J Ulevitch
Journal:  Am J Pathol       Date:  1978-11       Impact factor: 4.307

Review 4.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

5.  Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency.

Authors:  J B Ziegler; C A Alper; R S Rosen; P J Lachmann; L Sherington
Journal:  J Clin Invest       Date:  1975-03       Impact factor: 14.808

6.  Studies on C3 convertases. Inhibition of C5 convertase formation by peptides containing aromatic amino acids.

Authors:  A Kossorotow; W Opitz; E Etschenberg; U Hadding
Journal:  Biochem J       Date:  1977-11-01       Impact factor: 3.857

7.  Phospholipase A2 contamination of cobra venom factor preparations. Biologic role in complement-dependent in vivo reactions and inactivation with p-bromophenacyl bromide.

Authors:  J O Shaw; M F Roberts; R J Ulevitch; P Henson; E A Dennis
Journal:  Am J Pathol       Date:  1978-06       Impact factor: 4.307

8.  New synthetic inhibitor to the alternative complement pathway.

Authors:  N Ikari; Y Sakai; Y Hitomi; S Fujii
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

9.  Partial amino acid sequence of human factor D:homology with serine proteases.

Authors:  J E Volanakis; A Bhown; J C Bennett; J E Mole
Journal:  Proc Natl Acad Sci U S A       Date:  1980-02       Impact factor: 11.205

10.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.